Cite
HARVARD Citation
Cramer, P. et al. (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet oncology. 19 (9), pp. 1215-1228. [Online].